Capturing Value

Authors

  • G. Steven Burrill Burrill & Company

DOI:

https://doi.org/10.5912/jcb608

Keywords:

Pharmaceutical, biotech, value, reimbursement,

Abstract

Today’s pressure on pharmaceutical companies reflects greater pressures throughout the entire healthcare ecosystem as payers, patients, and providers wrestle with escalating costs and drive  healthcare systems around the world away from being cost-based to becoming value-based.  For pharmaceutical companies, this means not only a greater emphasis on creating value, but seeking new ways to capture value as well, particularly at a time when drugs will need to demonstrate they provide benefits commensurate with their costs and governments and payers squeeze down prices.    The challenge for drugmakers, broadly speaking, is to both find new ways to create value and capture value.

Author Biography

  • G. Steven Burrill, Burrill & Company
    G. Steven Burrill is CEO of Burrill & Company

Published

2013-04-01

Issue

Section

Commentary